#United States #Philadelphia #Verismo Therapeutics #KIR-CAR #SynKIR™-110

Promising Results from Verismo Therapeutics' STAR-101 Trial

Verismo Therapeutics has recently unveiled compelling early clinical data from its Phase 1 trial known as STAR-101. This trial evaluates the company's innovative SynKIR™-110 KIR-CAR therapy, designed for patients with hard-to-treat solid tumors that express mesothelin, such as ovarian cancer, mesothelioma, and cholangiocarcinoma. The findings were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 held in San Diego, CA, emphasizing the potential impact of this novel treatment.

The results indicate a favorable safety profile across multiple dose levels, demonstrating that none of the subjects experienced dose-limiting toxicities. Additionally, the preliminary efficacy signals suggest that as the dose increases, patients exhibit a significant biologic response, including the persistence of KIR-CAR T cells within the tumors. Dr. Laura Johnson, COO and CSO of Verismo, expressed optimism about these outcomes, noting that they mark an important achievement for the KIR-CAR platform technology.

Initial Trial Observations

The STAR-101 trial is an open-label, multicenter study that commenced in the United States to assess the safety and effectiveness of SynKIR™-110. Initial data derived from nine patients treated under three distinct dosing cohorts revealed promising findings. With no high-grade cytokine release syndrome (CRS) reported and only mild instances of Gr1-2 CRS observed, the safety profile appears robust. Furthermore, the infusion of SynKIR™-110 has led to substantial on-target biological activity, evidenced by measurable changes in the serum cytokines, indicating an effective immune response against the tumor cells.

Among the notable results, 33% of the participants in the highest dose cohort exhibited clinically meaningful anti-tumor activity. One patient achieved a partial response, which continues beyond three months, according to RECIST criteria. This promising outcome could suggest a shift in treatment modalities for patients with limited options.

Clinical Needs and Future Research

Given the association of mesothelin-expressing tumors with high mortality rates, the necessity for effective therapeutic options is paramount. As Dr. Janos L. Tanyi, the Principal Investigator and an associate professor at the University of Pennsylvania, stated, the trial’s findings illuminate a hopeful path forward. He pointed out the urgent medical need for improved treatments as previously available options often fall short in efficacy.

The STAR-101 trial has a dose-escalation design that is still ongoing, expanding the cohorts as data continues to affirm safety and efficacy. With the identification of a recommended Phase 2 dose on the horizon, Verismo Therapeutics remains committed to diligently progressing through the clinical trial phases.

About SynKIR™-110 KIR-CAR

The SynKIR™-110 KIR-CAR therapy is a first-of-its-kind autologous engineered T cell treatment. The design primarily focuses on utilizing a novel multi-chain architecture that enhances T cell functionality and longevity. These characteristics are essential for overcoming the inherent challenges posed by solid tumor microenvironments, which are often resistant to conventional CAR T therapies.

Verismo Therapeutics, a subsidiary of HLB Innovation, is spearheading advancements in KIR-CAR technology. With other ongoing projects within its pipeline, the company's commitment to addressing high unmet medical needs demonstrates its pivotal role in the evolution of cancer therapies. Their goal is to provide patients with more durable and effective treatment options, particularly for those facing aggressive forms of cancers.

This has sparked interest among healthcare professionals and the public alike, as innovative therapies like SynKIR™-110 may pave the way for significant progress in cancer treatment.

For further updates on Verismo Therapeutics and ongoing clinical trials, visit Verismo Therapeutics.